New Test to Predict Primary Melanoma Progression
21 January 2020
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.
A joint study led by researchers from Melanoma Institute Australia, The University of Sydney, Harvard Medical School, Sydney Local Health District and Adaptive Biotechnology analysed immune cells (known as T-cells) in primary melanoma samples taken from 209 patients, 164 of whom came from MIA.
The study, published today in Nature Cancer, found that patients with a T-cell fraction (TCFr) of less than 20% in their primary melanoma were two-and-a-half times more likely to have disease progression than those with more than 20% TCFr.
The study was jointly led by Dr James Wilmott and Co-Medical Director Professor Richard Scolyer from Melanoma Institute Australia and researchers from Harvard Medical School.
‘These findings suggest analysing TCFr in primary melanomas is a valuable tool for predicting which patients are at risk of developing metastatic melanoma, ’ Dr Wilmott said.
‘This could enable us to personalise treatment for each patient based on their individual risk of recurrence and progression, and potentially target them earlier with immunotherapy,’ Professor Scolyer added.
Australia has one of the highest melanoma rates in the world, with one person diagnosed every 30 minutes and one person dying every five hours from disease.
While 90% of early stage melanomas are cured with surgery alone, a subset of patients will recur metastatically within five years.
Recent advances in targeted and immunotherapies have significantly improved outcomes for Stage IV melanoma patients. However, the management of primary melanoma has remained relatively unchanged, with prognosis based principally on histopathological factors such as tumour thickness and ulceration.
‘This test offers the ability to identify primary melanoma patients at high risk of developing metastatic disease at their initial diagnosis,’ Dr Wilmott said. ‘These patients may benefit from close monitoring or the addition of adjuvant treatments to prevent their disease progressing.’
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
COVID restrictions continue to impact fundraising for melanoma services in Riverina.
Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.
More than 150 clinicians, researchers and MIA staff gathered online to share research highlights.
Independent researchers at The University of Sydney are seeking patient feedback.
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Postponed to early 2022. Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.